Pharma News and Headlines

Gibson Oncology and NIH Launch Phase 2 Trials of LMP744 Targeting First-Time Recurrent Glioblastoma

Gibson Oncology has launched a Phase 2 trial of its dual‑action drug LMP744 in patients with first‑time recurrent glioblastoma. The compound simultaneously inhibits topoisomerase 1 and down‑regulates the cMYC oncogene, aiming to disrupt tumor proliferation. The study will enroll about 40 patients, with tumor regression as the primary endpoint and survival metrics as secondary measures. Earlier Phase 1 work showed a favorable safety profile and tumor shrinkage in a subset of heavily pretreated cancer patients.